Reviewing the ketamine model for schizophrenia
The observation that antagonists of the N-methyl-D-aspartate receptor (NMDAR), such as phencyclidine (PCP) and ketamine, transiently induce symptoms of acute schizophrenia had led to a paradigm shift from dopaminergic to glutamatergic dysfunction in pharmacological models of schizophrenia. The gluta...
Saved in:
Published in | Journal of psychopharmacology (Oxford) Vol. 28; no. 4; p. 287 |
---|---|
Main Authors | , |
Format | Journal Article |
Language | English |
Published |
United States
01.04.2014
|
Subjects | |
Online Access | Get more information |
Cover
Loading…
Abstract | The observation that antagonists of the N-methyl-D-aspartate receptor (NMDAR), such as phencyclidine (PCP) and ketamine, transiently induce symptoms of acute schizophrenia had led to a paradigm shift from dopaminergic to glutamatergic dysfunction in pharmacological models of schizophrenia. The glutamate hypothesis can explain negative and cognitive symptoms of schizophrenia better than the dopamine hypothesis, and has the potential to explain dopamine dysfunction itself. The pharmacological and psychomimetic effects of ketamine, which is safer for human subjects than phencyclidine, are herein reviewed. Ketamine binds to a variety of receptors, but principally acts at the NMDAR, and convergent genetic and molecular evidence point to NMDAR hypofunction in schizophrenia. Furthermore, NMDAR hypofunction can explain connectional and oscillatory abnormalities in schizophrenia in terms of both weakened excitation of inhibitory γ-aminobutyric acidergic (GABAergic) interneurons that synchronize cortical networks and disinhibition of principal cells. Individuals with prenatal NMDAR aberrations might experience the onset of schizophrenia towards the completion of synaptic pruning in adolescence, when network connectivity drops below a critical value. We conclude that ketamine challenge is useful for studying the positive, negative, and cognitive symptoms, dopaminergic and GABAergic dysfunction, age of onset, functional dysconnectivity, and abnormal cortical oscillations observed in acute schizophrenia. |
---|---|
AbstractList | The observation that antagonists of the N-methyl-D-aspartate receptor (NMDAR), such as phencyclidine (PCP) and ketamine, transiently induce symptoms of acute schizophrenia had led to a paradigm shift from dopaminergic to glutamatergic dysfunction in pharmacological models of schizophrenia. The glutamate hypothesis can explain negative and cognitive symptoms of schizophrenia better than the dopamine hypothesis, and has the potential to explain dopamine dysfunction itself. The pharmacological and psychomimetic effects of ketamine, which is safer for human subjects than phencyclidine, are herein reviewed. Ketamine binds to a variety of receptors, but principally acts at the NMDAR, and convergent genetic and molecular evidence point to NMDAR hypofunction in schizophrenia. Furthermore, NMDAR hypofunction can explain connectional and oscillatory abnormalities in schizophrenia in terms of both weakened excitation of inhibitory γ-aminobutyric acidergic (GABAergic) interneurons that synchronize cortical networks and disinhibition of principal cells. Individuals with prenatal NMDAR aberrations might experience the onset of schizophrenia towards the completion of synaptic pruning in adolescence, when network connectivity drops below a critical value. We conclude that ketamine challenge is useful for studying the positive, negative, and cognitive symptoms, dopaminergic and GABAergic dysfunction, age of onset, functional dysconnectivity, and abnormal cortical oscillations observed in acute schizophrenia. |
Author | Frohlich, Joel Van Horn, John D |
Author_xml | – sequence: 1 givenname: Joel surname: Frohlich fullname: Frohlich, Joel organization: 1UCLA Center for Autism Research and Treatment (CART), University of California, Los Angeles, CA, USA – sequence: 2 givenname: John D surname: Van Horn fullname: Van Horn, John D |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/24257811$$D View this record in MEDLINE/PubMed |
BookMark | eNo1jktLxDAURoMozkP3riR_oGNy817KoKMwIIiuh7S510anD9qq6K93QF19m8M534Idt12LjF1IsZLSuSsBNngvpVRGQhDhiM2ltrJw4M2MLcbxVQhptTWnbAYajDuwc7Z6xI-Mn7l94VON_A2n2OQWedMl3HPqBj5Wdf7u-nrANsczdkJxP-L53y7Z8-3N0_qu2D5s7tfX26IyOkxFBNQxVnjIABElA0aR0k6IqozBByhV8jaWZbKEgKEKjgI5S2BS8opgyS5_vf172WDa9UNu4vC1-z8OP47xRZM |
CitedBy_id | crossref_primary_10_1093_schbul_sby190 crossref_primary_10_1097_FBP_0000000000000354 crossref_primary_10_3390_ijms23115968 crossref_primary_10_1016_j_biopha_2018_07_030 crossref_primary_10_1080_00952990_2018_1559849 crossref_primary_10_3389_fnins_2023_1177428 crossref_primary_10_1016_j_bbr_2022_113925 crossref_primary_10_1016_j_neuropharm_2016_10_002 crossref_primary_10_30756_ahmj_2023_10_01 crossref_primary_10_1038_s42003_023_04988_8 crossref_primary_10_1080_15592294_2024_2417158 crossref_primary_10_1007_s00213_022_06121_9 crossref_primary_10_1016_j_jpsychires_2021_08_010 crossref_primary_10_3390_ijms23105482 crossref_primary_10_3390_molecules24213993 crossref_primary_10_3389_fpsyt_2021_679960 crossref_primary_10_1016_j_pnpbp_2022_110560 crossref_primary_10_1016_j_euroneuro_2015_04_012 crossref_primary_10_3389_fnbeh_2020_00029 crossref_primary_10_3390_ph17040461 crossref_primary_10_1007_s00213_015_3946_6 crossref_primary_10_1016_j_bbr_2023_114614 crossref_primary_10_1093_ijnp_pyaa042 crossref_primary_10_1523_JNEUROSCI_1121_22_2022 crossref_primary_10_1016_j_clinph_2017_06_246 crossref_primary_10_1038_s41386_019_0328_5 crossref_primary_10_1016_j_neuroscience_2018_01_021 crossref_primary_10_1007_s00213_022_06090_z crossref_primary_10_1111_ajad_12984 crossref_primary_10_1016_j_jpsychires_2016_09_017 crossref_primary_10_1016_j_schres_2016_09_008 crossref_primary_10_1016_j_nlm_2021_107396 crossref_primary_10_3390_ijms24031913 crossref_primary_10_1016_j_pbb_2021_173287 crossref_primary_10_1016_j_nicl_2019_101739 crossref_primary_10_1007_s40138_019_00177_2 crossref_primary_10_1016_j_neuroscience_2020_09_029 crossref_primary_10_1038_mp_2017_6 crossref_primary_10_1186_s13104_022_06219_5 crossref_primary_10_1016_j_neuroscience_2015_06_059 crossref_primary_10_1016_j_bbr_2022_113964 crossref_primary_10_1016_j_biopha_2018_04_082 crossref_primary_10_1016_j_neuropharm_2024_110088 crossref_primary_10_1038_npp_2016_17 crossref_primary_10_1007_s00210_018_1552_y crossref_primary_10_1186_s13063_018_2831_0 crossref_primary_10_1002_hup_2738 crossref_primary_10_1016_j_physbeh_2015_05_013 crossref_primary_10_1007_s12031_020_01502_1 crossref_primary_10_1007_s00213_016_4401_z crossref_primary_10_3389_fnins_2022_1001869 crossref_primary_10_1007_s00213_015_4175_8 crossref_primary_10_17116_jnevro2021121091131 crossref_primary_10_1016_j_comppsych_2019_152122 crossref_primary_10_1016_j_neulet_2020_134984 crossref_primary_10_1007_s00406_023_01629_3 crossref_primary_10_1167_jov_21_6_9 crossref_primary_10_1016_j_neuropharm_2021_108896 crossref_primary_10_1016_j_pbb_2019_04_002 crossref_primary_10_1016_j_neuropharm_2018_01_005 crossref_primary_10_3389_fpsyt_2022_997758 crossref_primary_10_3390_jcm11071845 crossref_primary_10_1016_j_pnpbp_2023_110913 crossref_primary_10_1523_ENEURO_0406_22_2023 crossref_primary_10_1016_j_brainresbull_2021_07_004 crossref_primary_10_1016_j_bbr_2024_115231 crossref_primary_10_1016_j_schres_2015_11_006 crossref_primary_10_1080_17512433_2025_2459377 crossref_primary_10_1007_s12264_020_00507_5 crossref_primary_10_1155_2023_9093231 crossref_primary_10_1097_ALN_0000000000001513 crossref_primary_10_3389_fnins_2020_590088 crossref_primary_10_1007_s00204_021_03024_0 crossref_primary_10_1177_0269881118822263 crossref_primary_10_3389_fpsyt_2017_00037 crossref_primary_10_3389_fncir_2021_769969 crossref_primary_10_1016_j_psychres_2020_112938 crossref_primary_10_1097_FBP_0000000000000327 crossref_primary_10_1016_j_neuropharm_2022_108947 crossref_primary_10_1016_j_neubiorev_2018_07_001 crossref_primary_10_1186_s12868_015_0149_3 crossref_primary_10_1007_s00702_019_02081_1 crossref_primary_10_1016_j_jpsychires_2016_06_013 crossref_primary_10_1016_j_jpsychires_2016_12_003 crossref_primary_10_1016_j_imed_2022_03_001 crossref_primary_10_1038_s41386_024_01895_2 crossref_primary_10_1016_j_neuropharm_2018_06_008 crossref_primary_10_1016_j_psychres_2018_05_050 crossref_primary_10_1007_s43440_021_00232_4 crossref_primary_10_1016_j_neuroimage_2022_119624 crossref_primary_10_1016_j_neuropharm_2024_109970 crossref_primary_10_1177_0269881114553647 crossref_primary_10_3390_biomedicines13030649 crossref_primary_10_1007_s00702_024_02793_z crossref_primary_10_1111_bph_15487 crossref_primary_10_1016_j_biopha_2018_06_043 crossref_primary_10_1016_j_bbr_2024_115214 crossref_primary_10_1016_j_euroneuro_2015_04_004 crossref_primary_10_1162_CPSY_a_00005 crossref_primary_10_1177_0269881117748903 crossref_primary_10_23736_S2724_6612_21_02068_9 crossref_primary_10_3389_fnbeh_2017_00181 crossref_primary_10_1016_j_psychres_2016_01_023 crossref_primary_10_1097_FBP_0000000000000585 crossref_primary_10_3389_fpsyt_2022_737295 crossref_primary_10_1038_s41598_023_38258_8 crossref_primary_10_3390_ijms22179309 crossref_primary_10_1016_j_neuropharm_2020_108129 crossref_primary_10_1016_j_cortex_2016_03_017 crossref_primary_10_1016_j_pnpbp_2018_05_014 crossref_primary_10_1007_s00702_019_02080_2 crossref_primary_10_1080_14737175_2016_1174577 crossref_primary_10_1002_hup_2656 crossref_primary_10_1016_j_neuroscience_2020_05_012 crossref_primary_10_1186_s41983_023_00719_2 crossref_primary_10_1016_j_mehy_2016_05_032 crossref_primary_10_1016_j_neuroimage_2022_119004 crossref_primary_10_1016_j_acthis_2020_151531 crossref_primary_10_1016_j_phrs_2024_107085 crossref_primary_10_1016_j_neuint_2019_104503 crossref_primary_10_3389_fphar_2016_00348 crossref_primary_10_3389_fpsyt_2022_1017504 crossref_primary_10_1016_j_psychres_2021_114231 crossref_primary_10_3934_Neuroscience_2014_2_169 crossref_primary_10_1007_s00221_019_05556_5 crossref_primary_10_1016_j_schres_2019_11_041 crossref_primary_10_1016_j_cpr_2022_102231 crossref_primary_10_1016_j_pharmthera_2020_107520 crossref_primary_10_1016_j_schres_2020_06_028 crossref_primary_10_1051_jbio_2023028 crossref_primary_10_1097_NNR_0000000000000197 crossref_primary_10_2139_ssrn_3926148 crossref_primary_10_5607_en_2017_26_1_11 crossref_primary_10_1152_japplphysiol_00476_2020 crossref_primary_10_1016_j_bja_2018_01_022 crossref_primary_10_1021_acsptsci_4c00133 crossref_primary_10_1016_j_neuropharm_2016_01_035 crossref_primary_10_7554_eLife_56151 crossref_primary_10_1038_s41380_020_00878_1 crossref_primary_10_1016_j_coph_2014_11_006 crossref_primary_10_1038_s41380_021_01082_5 crossref_primary_10_1093_brain_awab095 crossref_primary_10_1371_journal_pone_0236363 crossref_primary_10_1016_j_neuroscience_2023_10_008 crossref_primary_10_1038_tp_2015_151 crossref_primary_10_1016_j_physbeh_2022_113708 crossref_primary_10_1016_j_pnpbp_2017_10_009 crossref_primary_10_3389_fpsyt_2021_671007 crossref_primary_10_3390_ijms21218048 crossref_primary_10_2174_2210303109666190619103230 crossref_primary_10_26599_BSA_2018_2018_9050009 crossref_primary_10_1016_j_heliyon_2024_e38986 crossref_primary_10_1007_s11011_021_00821_5 crossref_primary_10_1038_s41380_020_0793_6 crossref_primary_10_7554_eLife_53664 crossref_primary_10_1016_j_pnpbp_2020_110060 crossref_primary_10_1016_j_jbtep_2023_101891 crossref_primary_10_1016_j_schres_2020_09_013 crossref_primary_10_1111_ejn_14853 crossref_primary_10_3389_fpsyt_2017_00292 crossref_primary_10_1016_j_biopha_2021_112369 crossref_primary_10_1111_jnc_16133 crossref_primary_10_3389_fncel_2019_00499 crossref_primary_10_1016_j_ibneur_2023_12_012 crossref_primary_10_1016_j_bbr_2025_115441 crossref_primary_10_3390_brainsci13060848 crossref_primary_10_1016_j_pneurobio_2025_102718 crossref_primary_10_1371_journal_pcbi_1009280 crossref_primary_10_1007_s11682_014_9339_3 crossref_primary_10_1002_hbm_23294 crossref_primary_10_1016_j_biopsych_2019_07_011 crossref_primary_10_1016_j_pbb_2023_173658 crossref_primary_10_1016_j_neuroscience_2021_08_004 crossref_primary_10_1038_s41398_023_02344_2 crossref_primary_10_1038_s41467_024_48664_9 crossref_primary_10_1111_acem_13725 crossref_primary_10_3390_ijms23147800 crossref_primary_10_1007_s00213_019_05366_1 crossref_primary_10_1097_FBP_0000000000000289 crossref_primary_10_1111_ejn_14756 crossref_primary_10_3389_fnsys_2015_00190 crossref_primary_10_1177_02698811231187339 crossref_primary_10_1016_j_lfs_2020_117535 crossref_primary_10_1007_s00213_017_4807_2 crossref_primary_10_1002_cpt_3420 crossref_primary_10_1016_j_nicl_2018_09_001 crossref_primary_10_1371_journal_pone_0186732 crossref_primary_10_1016_j_brainresbull_2022_12_006 crossref_primary_10_1016_j_nlm_2020_107319 crossref_primary_10_1016_j_nicl_2018_05_037 crossref_primary_10_3389_fnsys_2022_963691 crossref_primary_10_1111_cns_14464 crossref_primary_10_1515_revneuro_2019_0090 crossref_primary_10_3389_fphar_2021_746935 crossref_primary_10_1007_s12264_018_0208_8 crossref_primary_10_1016_j_biopha_2023_114318 crossref_primary_10_1111_bph_13222 crossref_primary_10_1002_hbm_24838 crossref_primary_10_1016_j_schres_2016_10_027 crossref_primary_10_1177_23982128211055426 crossref_primary_10_1038_tp_2015_111 crossref_primary_10_3389_fpsyt_2021_786622 crossref_primary_10_3390_brainsci11070917 crossref_primary_10_1016_j_physbeh_2017_07_016 crossref_primary_10_1016_j_ajp_2024_104199 crossref_primary_10_1016_j_biopsych_2020_09_001 crossref_primary_10_3390_brainsci14121281 crossref_primary_10_3389_fnbeh_2022_1057319 crossref_primary_10_1007_s00406_024_01865_1 crossref_primary_10_1016_j_bbr_2020_112629 crossref_primary_10_3389_fnins_2019_00138 crossref_primary_10_3389_fnbeh_2016_00226 crossref_primary_10_1016_j_ntt_2022_107079 crossref_primary_10_1038_tp_2017_198 crossref_primary_10_1016_j_ejphar_2016_05_026 crossref_primary_10_1017_S1461145714000959 |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM |
DOI | 10.1177/0269881113512909 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | no_fulltext_linktorsrc |
Discipline | Psychology Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1461-7285 |
ExternalDocumentID | 24257811 |
Genre | Review Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
GrantInformation_xml | – fundername: NIBIB NIH HHS grantid: U54 EB005149 – fundername: NINDS NIH HHS grantid: R41 NS081792 – fundername: NINDS NIH HHS grantid: R41NS081792 – fundername: NIBIB NIH HHS grantid: 2U54EB005149 – fundername: NIBIB NIH HHS grantid: P41 EB015922 |
GroupedDBID | --- -TM -~X .2E .2F .2G .2J .2N 01A 0R~ 1~K 29L 31R 31S 31U 31X 31Y 31Z 4.4 53G 54M 5GY 5VS 6PF 85S AABMB AABOD AACKU AACMV AACTG AADUE AAEJI AAEWN AAGGD AAGLT AAGMC AAJIQ AAJOX AAJPV AAKGS AANSI AAPEO AAPII AAQDB AAQXH AAQXI AARDL AARIX AATAA AATBZ AAUAS AAWTL AAXOT AAYTG AAZBJ ABAWC ABAWP ABCCA ABCJG ABDWY ABEIX ABFWQ ABHKI ABHQH ABIDT ABIVO ABJIS ABJNI ABJZC ABKRH ABLUO ABNCE ABPGX ABPNF ABQKF ABQXT ABRHV ABUJY ABVFX ABVVC ABYTW ACARO ACDSZ ACDXX ACFEJ ACFMA ACFYK ACGBL ACGFS ACGZU ACJER ACJTF ACLFY ACLHI ACLZU ACNXM ACOFE ACOXC ACPRK ACROE ACRPL ACSIQ ACUAV ACUIR ACXKE ACXMB ADBBV ADDLC ADEBD ADEIA ADMPF ADNBR ADNMO ADNON ADRRZ ADSTG ADTBJ ADUKL ADVBO ADYCS ADZYD ADZZY AECGH AECVZ AEDTQ AEKYL AENEX AEPTA AEQLS AERKM AESZF AEUHG AEWDL AEWHI AEXFG AEXNY AFEET AFKBI AFKRG AFMOU AFQAA AFRAH AFUIA AFVCE AFWMB AGHKR AGKLV AGNHF AGPXR AGQPQ AGWFA AGWNL AHDMH AHHFK AIGRN AJABX AJEFB AJGYC AJMMQ AJSCY AJUZI AJVBE AJXAJ AJXGE ALKWR ALMA_UNASSIGNED_HOLDINGS AMCVQ ANDLU ARTOV ASPBG AUTPY AUVAJ AVWKF AYAKG AZFZN B3H B8M B8O B8R B8Z B93 B94 BBRGL BDDNI BKIIM BKSCU BPACV BSEHC BWJAD BYIEH C45 CAG CBRKF CDWPY CFDXU CGR COF CORYS CQQTX CS3 CUTAK CUY CVF DB0 DC- DC0 DD- DD0 DE- DF0 DO- DOPDO DU5 DV7 DV9 D~Y EBS ECM EIF EJD EMOBN F5P FEDTE FHBDP GROUPED_SAGE_PREMIER_JOURNAL_COLLECTION H13 HF~ HVGLF HZ~ IAO IEA IHR INH INR IVC J8X K.F K.J N9A NPM O9- OVD P.B P2P PQQKQ Q1R Q7K Q7L Q7R Q7U Q7X Q82 Q83 RIG ROL S01 SASJQ SAUOL SBI SCNPE SDB SFB SFC SFK SFT SGA SGO SGP SGR SGV SGX SGZ SHG SNB SPJ SPP SPQ SPV SQCSI STM TEORI UPT YQT ZONMY ZPPRI ZRKOI ZSSAH ZY4 |
ID | FETCH-LOGICAL-c549t-a2e4aace4252fffd5253f34700cba9892b3d86abbd6fe2e9c97f9f76f25dd83f2 |
IngestDate | Mon Jul 21 06:07:00 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 4 |
Keywords | N-methyl-D-aspartate receptor Ketamine schizophrenia glutamate |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c549t-a2e4aace4252fffd5253f34700cba9892b3d86abbd6fe2e9c97f9f76f25dd83f2 |
PMID | 24257811 |
ParticipantIDs | pubmed_primary_24257811 |
PublicationCentury | 2000 |
PublicationDate | 2014-04-01 |
PublicationDateYYYYMMDD | 2014-04-01 |
PublicationDate_xml | – month: 04 year: 2014 text: 2014-04-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Journal of psychopharmacology (Oxford) |
PublicationTitleAlternate | J Psychopharmacol |
PublicationYear | 2014 |
SSID | ssj0016465 |
Score | 2.5219815 |
SecondaryResourceType | review_article |
Snippet | The observation that antagonists of the N-methyl-D-aspartate receptor (NMDAR), such as phencyclidine (PCP) and ketamine, transiently induce symptoms of acute... |
SourceID | pubmed |
SourceType | Index Database |
StartPage | 287 |
SubjectTerms | Age of Onset Animals Dopamine - metabolism gamma-Aminobutyric Acid - metabolism Humans Ketamine - pharmacology Phencyclidine - pharmacology Receptors, N-Methyl-D-Aspartate - antagonists & inhibitors Schizophrenia - genetics Schizophrenia - physiopathology Schizophrenic Psychology |
Title | Reviewing the ketamine model for schizophrenia |
URI | https://www.ncbi.nlm.nih.gov/pubmed/24257811 |
Volume | 28 |
hasFullText | |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV07T8MwELZ4LCyI9xt5QEyktI7txCPioQoJxFBQt8p2zgIBbQVZ4NdzsZM2FIqAJYpsObL8Xc73PkIOEGOrZWqi2Pqi2ppHhglUVkAr4WRim7ow6F9dy_Ytv-yKbtXDvcwuyU3Dvn-bV_IfVHEMcS2yZP-A7OijOIDviC8-EWF8_grjYNivEp4eIdfPhdDou9v4-MHXekjdFDk05GENxyWsvf8_JBLW7AQXL4P7p4fQOOpyAKPAjDtkEO1BCAn2YThndUNCqx5_AoH5cdmKEhZa6FTckaU1KuB1Vhcuyq8s2DuBUbVTaVr0sS8kCl8BIa8hMnz2kHh9Jw3c9ufZiaLY1dQsmUX1oOh3WhhpSueR5FKMPdLHk1sp6j-Xyyd0CS9TdJbIYgkCPQnILpMZ6K-Qw5sAxdsR7YyT416P6CG9qYG0QhZGl9fbKmmMaIEiLdCKFqinBYpY0k-0sEZuL847p-2o7IURWdTg80gz4FpbwI0z51wmmIhdzJNm0xqtUsVMnKVSG5NJBwyUVYlTLpGOiSxLY8fWyVx_0IdNQgUw1QLTRIab8Qy05gngei10C1QCdotshEPpDUPBk151XNtTZ3bIwpikdsm8wz8M9lBcy82-B-cD_0A-pA |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Reviewing+the+ketamine+model+for+schizophrenia&rft.jtitle=Journal+of+psychopharmacology+%28Oxford%29&rft.au=Frohlich%2C+Joel&rft.au=Van+Horn%2C+John+D&rft.date=2014-04-01&rft.eissn=1461-7285&rft.volume=28&rft.issue=4&rft.spage=287&rft_id=info:doi/10.1177%2F0269881113512909&rft_id=info%3Apmid%2F24257811&rft_id=info%3Apmid%2F24257811&rft.externalDocID=24257811 |